Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1998 Dec 1;159(11):1368–1372.

Screening for prostate cancer: estimating the magnitude of overdetection

M McGregor 1, J A Hanley 1, J F Boivin 1, R G McLean 1
PMCID: PMC1229854  PMID: 9861205

Abstract

BACKGROUND: No randomized controlled trial of prostate cancer screening has been reported and none is likely to be completed in the near future. In the absence of direct evidence, the decision to screen must therefore be based on estimates of benefits and risks. The main risk of screening is overdetection--the detection of cancer that, if left untreated, would not cause death. In this study the authors estimate the level of overdetection that might result from annual screening of men aged 50-70. METHODS: The annual rate of lethal screen-detectable cancer (detectable cancer that would prove fatal before age 85 if left untreated) was calculated from the observed prostate cancer mortality rate in Quebec; the annual rate of all cases of screen-detectable prostate cancer was calculated from 2 recent screening studies. RESULTS: The annual rate of lethal screen-detectable prostate cancer was estimated to be 1.3 per 1000 men. The annual rate of all cases of screen-detectable prostate cancer was estimated to be 8.0 per 1000 men. The estimated case-fatality rate among men up to 85 years of age was 16% (1.3/8.0) (sensitivity analysis 13% to 22%). INTERPRETATION: Of every 100 men with screen-detected prostate cancer, only 16 on average (13 to 22) could have their lives extended by surgery, since the prostate cancer would not cause death before age 85 in the remaining 84 (78 to 87).

Full Text

The Full Text of this article is available as a PDF (113.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albertsen P. C., Fryback D. G., Storer B. E., Kolon T. F., Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995 Aug 23;274(8):626–631. [PubMed] [Google Scholar]
  2. Atkins D. Prostate cancer screening. JAMA. 1997 Jan 22;277(4):299–300. [PubMed] [Google Scholar]
  3. Bagshaw M. A., Cox R. S., Hancock S. L. Control of prostate cancer with radiotherapy: long-term results. J Urol. 1994 Nov;152(5 Pt 2):1781–1785. doi: 10.1016/s0022-5347(17)32385-6. [DOI] [PubMed] [Google Scholar]
  4. Carter H. B., Pearson J. D., Metter E. J., Brant L. J., Chan D. W., Andres R., Fozard J. L., Walsh P. C. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992 Apr 22;267(16):2215–2220. [PMC free article] [PubMed] [Google Scholar]
  5. Catalona W. J. Management of cancer of the prostate. N Engl J Med. 1994 Oct 13;331(15):996–1004. doi: 10.1056/NEJM199410133311507. [DOI] [PubMed] [Google Scholar]
  6. Catalona W. J., Richie J. P., Ahmann F. R., Hudson M. A., Scardino P. T., Flanigan R. C., deKernion J. B., Ratliff T. L., Kavoussi L. R., Dalkin B. L. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 May;151(5):1283–1290. doi: 10.1016/s0022-5347(17)35233-3. [DOI] [PubMed] [Google Scholar]
  7. Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. doi: 10.1056/NEJM199104253241702. [DOI] [PubMed] [Google Scholar]
  8. Chamberlain J., Melia J., Moss S., Brown J. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol. 1997 May;79 (Suppl 3):1–32. doi: 10.1111/j.1464-410x.1997.tb16914.x. [DOI] [PubMed] [Google Scholar]
  9. Chodak G. W., Thisted R. A., Gerber G. S., Johansson J. E., Adolfsson J., Jones G. W., Chisholm G. D., Moskovitz B., Livne P. M., Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994 Jan 27;330(4):242–248. doi: 10.1056/NEJM199401273300403. [DOI] [PubMed] [Google Scholar]
  10. Cohen R. J., Haffejee Z., Steele G. S., Nayler S. J. Advanced prostate cancer with normal serum prostate-specific antigen values. Arch Pathol Lab Med. 1994 Nov;118(11):1123–1126. [PubMed] [Google Scholar]
  11. Coley C. M., Barry M. J., Fleming C., Fahs M. C., Mulley A. G. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med. 1997 Mar 15;126(6):468–479. doi: 10.7326/0003-4819-126-6-199703150-00010. [DOI] [PubMed] [Google Scholar]
  12. Collins M. M., Barry M. J. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate. JAMA. 1996 Dec 25;276(24):1976–1979. [PubMed] [Google Scholar]
  13. Fowler F. J., Jr, Barry M. J., Lu-Yao G., Roman A., Wasson J., Wennberg J. E. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993 Dec;42(6):622–629. doi: 10.1016/0090-4295(93)90524-e. [DOI] [PubMed] [Google Scholar]
  14. Gann P. H., Hennekens C. H., Stampfer M. J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995 Jan 25;273(4):289–294. [PubMed] [Google Scholar]
  15. Goldacre M. J. Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health. 1993 Dec;47(6):491–496. doi: 10.1136/jech.47.6.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hirst G. H., Ward J. E., Del Mar C. B. Screening for prostate cancer: the case against. Med J Aust. 1996 Mar 4;164(5):285–288. doi: 10.5694/j.1326-5377.1996.tb94192.x. [DOI] [PubMed] [Google Scholar]
  17. Johansson J. E., Holmberg L., Johansson S., Bergström R., Adami H. O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997 Feb 12;277(6):467–471. [PubMed] [Google Scholar]
  18. Labrie F., Candas B., Cusan L., Gomez J. L., Diamond P., Suburu R., Lemay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology. 1996 Feb;47(2):212–217. doi: 10.1016/S0090-4295(99)80419-1. [DOI] [PubMed] [Google Scholar]
  19. Labrie F., Dupont A., Suburu R., Cusan L., Gomez J. L., Koutsilieris M., Diamond P., Emond J., Lemay M., Candas B. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin Invest Med. 1993 Dec;16(6):425–439. [PubMed] [Google Scholar]
  20. Lu-Yao G. L., Yao S. L. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997 Mar 29;349(9056):906–910. doi: 10.1016/S0140-6736(96)09380-4. [DOI] [PubMed] [Google Scholar]
  21. Murphy G. P., Mettlin C., Menck H., Winchester D. P., Davidson A. M. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol. 1994 Nov;152(5 Pt 2):1817–1819. doi: 10.1016/s0022-5347(17)32392-3. [DOI] [PubMed] [Google Scholar]
  22. Pearson J. D., Carter H. B. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol. 1994 Nov;152(5 Pt 2):1743–1748. doi: 10.1016/s0022-5347(17)32375-3. [DOI] [PubMed] [Google Scholar]
  23. Percy C., Stanek E., 3rd, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health. 1981 Mar;71(3):242–250. doi: 10.2105/ajph.71.3.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schmidt J. D., Mettlin C. J., Natarajan N., Peace B. B., Beart R. W., Jr, Winchester D. P., Murphy G. P. Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol. 1986 Aug;136(2):416–421. doi: 10.1016/s0022-5347(17)44889-0. [DOI] [PubMed] [Google Scholar]
  25. Schröder F. H. Screening, early detection, and treatment of prostate cancer: a European view. Urology. 1995 Sep;46(3 Suppl A):62–70. doi: 10.1016/s0090-4295(99)80252-0. [DOI] [PubMed] [Google Scholar]
  26. Smith D. S., Catalona W. J., Herschman J. D. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996 Oct 23;276(16):1309–1315. [PubMed] [Google Scholar]
  27. Wasson J. H., Cushman C. C., Bruskewitz R. C., Littenberg B., Mulley A. G., Jr, Wennberg J. E. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med. 1993 May;2(5):487–493. doi: 10.1001/archfami.2.5.487. [DOI] [PubMed] [Google Scholar]
  28. Woolf S. H. Should we screen for prostate cancer? BMJ. 1997 Apr 5;314(7086):989–990. doi: 10.1136/bmj.314.7086.989. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES